Page last updated: 2024-08-23

cabergoline and Cirrhosis

cabergoline has been researched along with Cirrhosis in 13 studies

Research

Studies (13)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's7 (53.85)29.6817
2010's5 (38.46)24.3611
2020's1 (7.69)2.80

Authors

AuthorsStudies
Albarel, F; Amodru, V; Brue, T; Castinetti, F; Cuny, T; Dufour, H; Graillon, T; Morange, I1
Chia, YY; Goh, GH; Mohan, N; Teo, K; Ting, E; Yeo, TT1
Ariano, C; De Vecchis, R; Esposito, C1
Andersohn, F; Garbe, E1
Bridgman, P; Cawood, TJ; Cole, D; Hunter, L1
Bhattacharyya, S; Davar, J; Mikhailidis, DP; Schapira, AH1
Cramer, MJ; Lafeber, M; Stades, AM; Teding van Berkhout, F; Valk, GD; Zelissen, PM1
Bötzel, K; Levin, J; Näbauer, M; Neudert, J; Zwermann, L1
Elenkova, A; Kalinov, K; Shabani, R; Zacharieva, S1
MacIver, DH; Townsend, M1
Basu, S; Chaudhuri, KR; Dhawan, V; Jackson, G; Odin, P1
Basu, S; Chaudhuri, KR; Dhawan, V; Jackson, G; Luce, P; Medcalf, P; Odin, P; Stegie, F1
Fuhrmann, JT; Junghanns, S; Koch, R; Oelwein, C; Reichmann, H; Simonis, G; Storch, A; Strasser, RH1

Reviews

3 review(s) available for cabergoline and Cirrhosis

ArticleYear
The risks of medical treatment of prolactinoma.
    Annales d'endocrinologie, 2021, Volume: 82, Issue:1

    Topics: Cabergoline; Dopamine Agonists; Drug-Related Side Effects and Adverse Reactions; Fibrosis; Heart Valve Diseases; Humans; Neurosurgical Procedures; Pituitary Neoplasms; Prolactinoma; Substance-Related Disorders

2021
Cabergoline use and risk of fibrosis and insufficiency of cardiac valves. Meta-analysis of observational studies.
    Herz, 2013, Volume: 38, Issue:8

    Topics: Cabergoline; Dopamine Agonists; Ergolines; Female; Fibrosis; Heart Valve Diseases; Humans; Male; Myocardium; Observational Studies as Topic; Prevalence; Risk Factors

2013
Drug-induced fibrotic valvular heart disease.
    Lancet (London, England), 2009, Aug-15, Volume: 374, Issue:9689

    Topics: Antiparkinson Agents; Appetite Depressants; Cabergoline; Dexfenfluramine; Dopamine Agonists; Drug Monitoring; Ergolines; Ergotamine; Fenfluramine; Fibrosis; Heart Valve Diseases; Heart Valves; Humans; Methysergide; Migraine Disorders; N-Methyl-3,4-methylenedioxyamphetamine; Patient Selection; Pergolide; Receptors, Serotonin; Serotonin Agents; Serotonin Plasma Membrane Transport Proteins; Vasoconstrictor Agents

2009

Trials

1 trial(s) available for cabergoline and Cirrhosis

ArticleYear
Valvular heart disease in Parkinson's disease patients treated with dopamine agonists: a reader-blinded monocenter echocardiography study.
    Movement disorders : official journal of the Movement Disorder Society, 2007, Jan-15, Volume: 22, Issue:2

    Topics: Benzothiazoles; Cabergoline; Dopamine Agonists; Double-Blind Method; Echocardiography; Ergolines; Female; Fibrosis; Heart Valve Diseases; Humans; Hypertrophy, Left Ventricular; Indoles; Male; Middle Aged; Mitral Valve Insufficiency; Parkinson Disease; Pergolide; Pramipexole; Severity of Illness Index; Tricuspid Valve Insufficiency

2007

Other Studies

9 other study(ies) available for cabergoline and Cirrhosis

ArticleYear
Cabergoline-induced fibrosis of prolactinomas: a neurosurgical perspective.
    BMJ case reports, 2017, Nov-03, Volume: 2017

    Topics: Adult; Antineoplastic Agents; Cabergoline; Combined Modality Therapy; Diagnosis, Differential; Dopamine Agonists; Ergolines; Fibrosis; Humans; Hypogonadism; Hypothyroidism; Magnetic Resonance Imaging; Male; Pituitary Neoplasms; Prolactinoma; Thyroxine; Tricuspid Valve Insufficiency

2017
Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists.
    Movement disorders : official journal of the Movement Disorder Society, 2009, Jan-15, Volume: 24, Issue:1

    Topics: Aged; Aged, 80 and over; Apomorphine; Benzothiazoles; Bromocriptine; Cabergoline; Databases, Factual; Dopamine Agonists; Endomyocardial Fibrosis; Ergolines; Female; Fibrosis; Heart Valve Diseases; Humans; Indoles; Male; Middle Aged; Pergolide; Pericarditis; Pleural Diseases; Pramipexole; Pulmonary Fibrosis; Retroperitoneal Fibrosis; Tetrahydronaphthalenes; Thiophenes; United States

2009
Low-dose cabergoline causing valvular heart disease in a patient treated for prolactinoma.
    Internal medicine journal, 2009, Volume: 39, Issue:4

    Topics: Brain Ischemia; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Ergolines; Fatal Outcome; Fibrosis; Heart Valve Prosthesis Implantation; Humans; Intestinal Obstruction; Male; Middle Aged; Mitral Valve Insufficiency; Pituitary Neoplasms; Prolactinoma; Tricuspid Valve Insufficiency; Ventricular Dysfunction, Left

2009
Absence of major fibrotic adverse events in hyperprolactinemic patients treated with cabergoline.
    European journal of endocrinology, 2010, Volume: 162, Issue:4

    Topics: Acromegaly; Blood Sedimentation; C-Reactive Protein; Cabergoline; Creatinine; Cross-Sectional Studies; Dopamine Agonists; Echocardiography; Electrocardiography; Ergolines; Female; Fibrosis; Glomerular Filtration Rate; Heart Valve Diseases; Heart Valves; Humans; Hyperprolactinemia; Lung; Lung Diseases; Male; Middle Aged; Respiratory Function Tests; Retroperitoneal Fibrosis; Statistics, Nonparametric

2010
Reversible cardiac valve fibrosis secondary to treatment with high-dose cabergoline for Parkinson's disease.
    Journal of neurology, 2011, Volume: 258, Issue:11

    Topics: Antiparkinson Agents; Cabergoline; Echocardiography, Doppler, Color; Ergolines; Fibrosis; Heart Valve Diseases; Heart Valves; Humans; Male; Middle Aged; Parkinson Disease

2011
Increased prevalence of subclinical cardiac valve fibrosis in patients with prolactinomas on long-term bromocriptine and cabergoline treatment.
    European journal of endocrinology, 2012, Volume: 167, Issue:1

    Topics: Adult; Antineoplastic Agents; Bromocriptine; Cabergoline; Case-Control Studies; Dopamine Agonists; Echocardiography; Ergolines; Female; Fibrosis; Heart Valve Diseases; Heart Valves; Humans; Male; Middle Aged; Pituitary Neoplasms; Prevalence; Prolactinoma; Prospective Studies

2012
Constrictive pericarditis and pleuropulmonary fibrosis secondary to cabergoline treatment for Parkinson's disease.
    Heart (British Cardiac Society), 2004, Volume: 90, Issue:8

    Topics: Antiparkinson Agents; Cabergoline; Ergolines; Fibrosis; Humans; Male; Middle Aged; Parkinson Disease; Pericarditis, Constrictive; Pleura; Pulmonary Fibrosis

2004
Valvular heart disease and fibrotic reactions may be related to ergot dopamine agonists, but non-ergot agonists may also not be spared.
    Movement disorders : official journal of the Movement Disorder Society, 2004, Volume: 19, Issue:12

    Topics: Aortic Valve; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Fibrosis; Heart Valve Diseases; Humans; Parkinson Disease; Pergolide

2004
Retrospective evaluation of cardio-pulmonary fibrotic side effects in symptomatic patients from a group of 234 Parkinson's disease patients treated with cabergoline.
    Journal of neural transmission (Vienna, Austria : 1996), 2005, Volume: 112, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Cabergoline; Ergolines; Female; Fibrosis; Heart Valve Diseases; Humans; Male; Middle Aged; Parkinson Disease; Pulmonary Fibrosis; Retroperitoneal Fibrosis; Retrospective Studies

2005